KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Operating Income

Last Annual Value

-46.15M

3-Year CAGR

-49%

5-Year CAGR

8%

10-Year CAGR

4%

KT

Kalaris Therapeutics Inc Competitors Analysis of Operating Income

KLRS · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-46.15M
N/AN/AN/A 
-42.44M
N/AN/AN/A
-90.61M
N/AN/AN/A
-51.51M
N/AN/AN/A
-39.70M
N/AN/AN/A
-96.01M
N/AN/AN/A
-139.16M
N/AN/AN/A
-100.85M
N/AN/AN/A
-96.82M
N/AN/AN/A
-36.51M
N/AN/AN/A
-15.09M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7